ClinicalTrials.gg
TerminatedNCT00109772CRPS-002Updated Aug 28, 2013Results posted

Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1

A Phase 2 interventional study of lenalidomide and Placebo in Complex Regional Pain Syndrome, Type I, sponsored by Celgene Corporation. Terminated at 27 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-28.

Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Why this study was terminated
Interim analysis showed the primary outcome was not reached

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 15 studies in Reflex Sympathetic Dystrophy with a site in United States — 2 open to participants now, 2 under way, 1 of them phase 3. Reflex Sympathetic Dystrophy · United States.

Enrollment
5th of 12
184 · median 113
Started
2005
the only one that year
Phase 2
3 of 15
none open now
Registered
4th of 15
by date
Lead sponsor
2 of 15
Celgene Corporation

Among the 15 studies in Reflex Sympathetic Dystrophy with a site in United States, this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2005, is one of 3 in phase 2, and was the 4th registered.

Reflex Sympathetic Dystrophy

43 studies on the registry are indexed under Reflex Sympathetic Dystrophy; 4 are open to participants now.

Browse Reflex Sympathetic Dystrophy studies →

Open to participants now

2 of the 15 studies in Reflex Sympathetic Dystrophy with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Reflex Sympathetic Dystrophy studies recruiting now, 3 set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Reflex Sympathetic Dystrophy with a site in United States, or all of them as a file.
02

Study summary

The purpose of this multicenter, double-blind, placebo-controlled study is to evaluate the efficacy and safety of Lenalidomide in adult subjects with Complex Regional Pain Syndrome (CRPS) Type 1.

Read the detailed description

This is a multicenter, double-blind, placebo-controlled study in adult subjects with Complex Regional Pain Syndrome (CRPS) Type 1.

One hundred eighty (180) subjects diagnosed with unilateral CRPS Type 1 will be enrolled and randomized to receive orally either 10 mg/day of lenalidomide or placebo (90 subjects per treatment arm). For each subject, the study consists of three phases: Pre-randomization Phase (2 weeks), Treatment Phase (12 weeks) and Extension Phase where subjects have the opportunity to receive lenalidomide treatment as long as a benefit is derived from the drug. Subjects who complete all 12 weeks of the treatment phase may be eligible to receive lenalidomide in the extension phase. Subject may continue in the extension phase as long as a benefit is derived from the drug.

03

Conditions studied

  • Complex Regional Pain Syndrome, Type I

Keywords

  • CRPS
  • RSDS
  • Pain
  • CC-5013
  • Revlimid
  • Complex Regional Pain Syndrome
  • Reflex Sympathy Dystrophy Syndrome
  • Lenalidomide
  • CRPS Type I
  • Celgene
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 18 years at the time of signing the form
  • Understand and voluntarily sign an informed consent form
  • A diagnosis of CRPS Type 1, as defined by modified International Association for the Study of Pain criteria for at least a one-year duration. Unilateral involvement of a distal limb (hand or foot) with or without proximal spread must be present. In the presence of upper and lower limb involvement, the most severely affected limb will be designated the CRPS-affected limb.
  • Screening: CRPS pain intensity score in the CRPS-affected limb must be at least 4 on an 11-point (0-10) Pain Intensity Numerical Rating Scale (PI-NRS).
  • Randomization: Average PI-NRS score for randomization purposes will be based on AM and PM assessments made during the 7 days prior to randomization. At least eight PI-NRS scores during this 7-day period are required and the Average PI-NRS score in the CRPS-affected limb during this period must be at least 4 on an 11-point (0-10) PI-NRS.
  • Measurable (by electrophysiology methods) sural, median sensory, median motor and peroneal motor nerves at the screening nerve conduction study.
  • Opioid analgesics, non-opioid analgesics, non-steroidal anti-inflammatory drugs, anticonvulsants, antidepressant drugs and other non-drug therapies may be continued provided that the subject is on stable doses/regimens for at least four weeks prior to the start of the Treatment Phase (Visit 2).
  • Able to adhere to the study visit schedule and other protocol requirements.
  • Women of (WCBP) must agree to practice complete abstinence from heterosexual intercourse or to use two methods of beginning 4 weeks prior to the start of study drug (Day 1) while on study drug (including dose interruptions) and 4 weeks after the last dose of study drug. The two methods of contraception must include one highly effective method (i.e. intrauterine device [IUD], hormonal [birth control pills, injections, or implants only if used in conjunction with a low-dose (81 mg/day) aspirin regimen], tubal ligation, partner's vasectomy) and one additional effective (barrier) method (i.e. latex condom, diaphragm, cervical cap). If a hormonal method (birth control pills, injections, or implants) or IUD is not medically possible for the subject, two of the barrier methods will be acceptable.
  • Women of childbearing potential (WCBP) must have two negative pregnancy tests (sensitivity of at least 50 mlU/mL) prior to starting study drug treatment. The first test should be performed within 10-14 days and the second within 24 hours of starting study drug. Once treatment has started, it is recommended that subjects have weekly pregnancy test during the first 4 weeks of treatment. Thereafter, subjects are required to have pregnancy testing every 4 weeks in females with regular menstrual cycles and every 2 weeks in females with irregular cycles.
  • Males (including those who have had a vasectomy) must use barrier contraception (latex condoms) when engaging in reproductive sexual activity with WCBP while on study drug and for 4 weeks after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a subject from study enrollment:

  • History of deep vein thrombosis (DVT) or stroke in the past 5 years.
  • Documented peripheral neuropathies to include diabetic neuropathy and other metabolic or toxic neuropathies.
  • Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematological, endocrine, pulmonary, cardiac, neurological or cerebral disease.
  • Any other serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the form.
  • White blood cell count (WBC) \< 3.5*10\^9/L at screening.
  • , (ALT), aspartate transaminase (AST) or alkaline phosphatase levels more than two times the at screening.
  • Abnormal thyroid function test values at screening.
  • Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  • Use of concomitant medication(s), which could increase the risk for developing DVT, except for -based (oral injectable, implantable) and hormone replacement therapies only if used in conjunction with a low-dose (81 mg/day) aspirin regimen.
  • Concurrent use of thalidomide.
  • Prior development of an allergic reaction/ while taking thalidomide.
  • Prior development of a moderate or severe rash or any desquamation while taking thalidomide.
  • Prior treatment with lenalidomide.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
184 participants (actual)

Study arms

  • Experimental
    lenalidomide

    10 mg/day lenalidomide orally for up to 12 weeks in the double-blind treatment period. Participants who completed double-blind treatment had the option of continuing on lenalidomide in the open-label extension period for as long as benefit was derived from the drug or until study closure.

    Drug: lenalidomide

  • Placebo comparator
    Placebo

    Placebo orally for up to 12 weeks in the double-blind treatment period. Participants who completed double-blind treatment had the option of crossing over to lenalidomide 10mg in the open-label extension period for as long as benefit was derived from the drug or until study closure.

    Drug: Placebo

Interventions

  • Two 5 mg capsules taken one time per day

    Also known as: Revlimid, CC-5013

  • DrugPlacebo

    Two placebo capsules taken one time per day

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Have a >= 30% Reduction (Improvement) in the Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score From Baseline to the Last Assessment

    Participants rated the intensity of pain in the CRPS-affected limb twice each day in a diary. The PI-NRS is an eleven point scale with 0=no pain and 10=worst pain imaginable. Responders are participants who completed 12 weeks of treatment and their week 12 PI-NRS score showed at least a 30% improvement from baseline. Participants who did not complete 12 weeks of treatment are considered non-responders.

    Time frame: Day 0, Week 12

Secondary outcomes

  1. Change From Baseline in the Total Score of the Short Form McGill Pain Questionnaire (SF-MPQ) at Week 12

    Short Form McGill Pain Questionnaire (SF-MPQ) is comprised of 15 pain qualities that are rated by the participant on a 4 point scale with 0=none and 3=severe. The scale for the Total Score is 0-45. Week 12 values are compared to baseline values. Negative changes indicate improvement in level of pain.

    Time frame: Day 0, week 12

  2. Change From Baseline in the Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score Using Averaged Morning and Evening Readings at Week 12

    Participants rated the intensity of pain in the CRPS-affected limb twice each day in a diary. Morning and evening scores are averaged. The PI-NRS is an eleven point scale with 0=no pain and 10=worst pain imaginable. Week 12 values are compared to baseline values. Negative changes indicate improvement in level of pain.

    Time frame: Day 0, week 12

  3. Change From Baseline in the Morning Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score at Week 12

    Participants rated the intensity of pain in the CRPS-affected limb twice each day in a diary. The PI-NRS is an eleven point scale with 0=no pain and 10=worst pain imaginable. The morning pain ratings at baseline and Week 12 are compared. Negative changes indicate improvement in level of pain.

    Time frame: Day 0, week 12

  4. Change From Baseline in the Evening Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score at Week 12

    Participants rated the intensity of pain in the CRPS-affected limb twice each day in a diary. The PI-NRS is an eleven point scale with 0=no pain and 10=worst pain imaginable. The evening pain ratings at baseline and Week 12 are compared. Negative changes indicate improvement in level of pain.

    Time frame: Day 0, week 12

  5. Change From Baseline in Daily Sleep Assessment Average Score at Week 12

    Participants rated how much CRPS pain interfered with their sleep each day in a diary. The Sleep Assessment uses an eleven point scale for four questions. Questions concern ability to fall asleep, ability to stay asleep, how refreshed the participant feels upon waking and how alert the participant is during the day. All use a scale of 0-10, where the higher number is the positive response (e.g. 0=Pain completely interferes with sleep and 10=Pain does not interfere). The mean of all four responses was calculated if at least 3 of the 4 questions had a value. Week 12 values are compared to baseline values. Positive change values indicate improvement.

    Time frame: Day 0, week 12

  6. Change From Baseline in Activity Level Rating Using a Numeric Rating Scale (NRS) at Week 12

    Participants rated how the activity level on a given day compares with their activity level prior to the start of treatment. A seven-point scale is used with -3=much worse and +3=much better. Positive change values indicate improvement.

    Time frame: Day 0, week 12

  7. Change From Baseline in Participant Assessment of CRPS Symptoms Total Score at Week 12

    Participants rated twelve CRPS symptoms using a four-point rating scale in which 1=the most positive outcome and 4= the most negative outcome for a total scale of 12-48. Week 12 values are compared to baseline values. Negative change values indicate improvement.

    Time frame: Day 0, week 12

  8. Change From Baseline in "Mechanically Evoked" (Allodynia) Numeric Rating Scale (NRS) Score at Week 12

    The investigator rated the degree of allodynia on both the CRPS-affected limb on an eleven-point scale where 0=no pain and 10=worst pain imaginable. This outcome compares the baseline values for the CRPS affected-limb to the values at week 12. Negative change values indicate improvement.

    Time frame: Day 0, week 12

  9. Difference in Allodynia Rating Between the CRPS-affected Limb and the Normal Limb at Week 12

    The investigator rated the degree of allodynia on both the CRPS-affected limb and the normal (or less-affected) limb on an eleven-point scale where 0=no pain and 10=worst pain imaginable. This outcome compares the values for the CRPS affected-limb to the normal limb at week 12.

    Time frame: Week 12

  10. Change From Baseline in the Brief Pain Inventory (BPI) Total Score at Week 12

    Participants completed the Brief Pain Inventory which asks twelve questions that are rated on an eleven-point scale in which 0=most positive outcome and 10=the most negative outcome for a total scale of 0-120. BPI contains questions that concern the level of pain over the last week and the level of pain right now, the extent to which pain interfered with sleep, normal activities, ability to work, relationships, walking etc. Week 12 values are compared to baseline values. Negative change values indicate improvement.

    Time frame: Day 0, week 12

  11. Change From Baseline in the Profile of Mood States (POMS) at Week 12

    Participants completed the Profile of Mood States questionnaire that asks participants to rate how each of 65 words reflected their mood in the past week on a 5-point scale with 0=not at all and 4=extremely for a total scale of 0-260. Week 12 values are compared to baseline values. Negative change values indicate improvement.

    Time frame: Day 0, week 12

  12. Patient Global Impression of Change (PGIC) at Week 12

    The Patient Global Impression of Change asks the question: Overall, how would you rate your CRPS condition since the start of study drug? Answers are represented on a seven-point scale with -3=much worst and +3=much better.

    Time frame: Week 12

  13. Participants Who Had a Change to CRPS Pain Medication During the Treatment Period

    Participants who had any change in CRPS medication during the double-blind treatment period (up to week 12) are summarized. Changes include additions, discontinuations or dosage change of CRPS medication(s).

    Time frame: Day 1 to week 12

  14. Change From Baseline in the Maximal Composite Motor Nerve Conduction Velocity at Week 12

    An electrophysiological evaluation using standard electrophysiological and electromyography to measure the speed and extent of nerve conduction. Week 12 values are compared to baseline values for maximal motor nerve conduct velocity.

    Time frame: Day 0, week 12

  15. Change From Baseline in the Maximal Composite Sensory Nerve Conduction Velocity at Week 12

    An electrophysiological evaluation using standard electrophysiological and electromyography to measure the speed and extent of nerve conduction. Week 12 values are compared to baseline values for maximal sensory nerve conduct velocity.

    Time frame: Day 0, week 12

  16. Participants With Treatment-Emergent Adverse Events in the Double-Blind Period or the Extension Period

    Counts of study participants who had adverse events (AEs) while treated in either the Double-blind or Extension Periods. The NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 was used by the investigator to grade the severity of the AEs: Grade 1=Mild AE, Grade 2=Moderate AE, Grade 3=Severe AE, Grade 4=Life-threatening or disabling AE, Grade 5=Death related to AE. AEs are also summarized by whether they were serious, related to treatment and whether the AE caused treatment to be altered. A serious AE (SAE) was any event that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or congenital anomaly/birth defect or was an important medical event could have jeopardized the patient's safety or required medical or surgical intervention to prevent one of the outcomes listed above.

    Time frame: Day 1 up to week 158

07

Results

Posted Aug 28, 2013

Participant flow

Double-blind Treatment
Participant flow — Double-blind Treatment
MilestoneLenalidomidePlacebo to Lenalidomide
Started9094
Safety and itt population8793
Completed6879
Not completed2215
Withdrew: Adverse event145
Withdrew: Lack of efficacy10
Withdrew: Withdrawal by subject21
Withdrew: Lost to follow-up23
Withdrew: Protocol violation01
Withdrew: Other04
Withdrew: Withdrew prior to treatment31
Open-label Extension
Participant flow — Open-label Extension
MilestoneLenalidomidePlacebo to Lenalidomide
Started6478
Completed1929
Not completed4549
Withdrew: Adverse event1019
Withdrew: Lack of efficacy1911
Withdrew: Withdrawal by subject96
Withdrew: Lost to follow-up10
Withdrew: Death01
Withdrew: Protocol violation22
Withdrew: Other410

Outcome measures

PrimaryPercentage of Participants Who Have a >= 30% Reduction (Improvement) in the Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score From Baseline to the Last Assessment

Participants rated the intensity of pain in the CRPS-affected limb twice each day in a diary. The PI-NRS is an eleven point scale with 0=no pain and 10=worst pain imaginable. Responders are participants who completed 12 weeks of treatment and their week 12 PI-NRS score showed at least a 30% improvement from baseline. Participants who did not complete 12 weeks of treatment are considered non-responders.

Time frame:
Day 0, Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Have a >= 30% Reduction (Improvement) in the Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score From Baseline to the Last Assessment
percentage of participantsLenalidomidePlacebo to Lenalidomide
Responders16.116.1
Non-responders83.983.9
Statistical analysis
  • Lenalidomide vs Placebo to Lenalidomide · Cochran-Mantel-Haenszel · p = .8940controlled for centers
SecondaryChange From Baseline in the Total Score of the Short Form McGill Pain Questionnaire (SF-MPQ) at Week 12

Short Form McGill Pain Questionnaire (SF-MPQ) is comprised of 15 pain qualities that are rated by the participant on a 4 point scale with 0=none and 3=severe. The scale for the Total Score is 0-45. Week 12 values are compared to baseline values. Negative changes indicate improvement in level of pain.

Time frame:
Day 0, week 12
Reported as:
Mean · units on a scale
Change From Baseline in the Total Score of the Short Form McGill Pain Questionnaire (SF-MPQ) at Week 12
units on a scaleLenalidomidePlacebo to Lenalidomide
Change From Baseline in the Total Score of the Short Form McGill Pain Questionnaire (SF-MPQ) at Week 12-5.2 ± 9.15-3.0 ± 9.37
SecondaryChange From Baseline in the Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score Using Averaged Morning and Evening Readings at Week 12

Participants rated the intensity of pain in the CRPS-affected limb twice each day in a diary. Morning and evening scores are averaged. The PI-NRS is an eleven point scale with 0=no pain and 10=worst pain imaginable. Week 12 values are compared to baseline values. Negative changes indicate improvement in level of pain.

Time frame:
Day 0, week 12
Reported as:
Mean · units on a scale
Change From Baseline in the Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score Using Averaged Morning and Evening Readings at Week 12
units on a scaleLenalidomidePlacebo to Lenalidomide
Change From Baseline in the Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score Using Averaged Morning and Evening Readings at Week 12-0.6 ± 1.65-0.4 ± 1.50
SecondaryChange From Baseline in the Morning Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score at Week 12

Participants rated the intensity of pain in the CRPS-affected limb twice each day in a diary. The PI-NRS is an eleven point scale with 0=no pain and 10=worst pain imaginable. The morning pain ratings at baseline and Week 12 are compared. Negative changes indicate improvement in level of pain.

Time frame:
Day 0, week 12
Reported as:
Mean · units on a scale
Change From Baseline in the Morning Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score at Week 12
units on a scaleLenalidomidePlacebo to Lenalidomide
Change From Baseline in the Morning Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score at Week 12-0.6 ± 1.67-0.4 ± 1.53
SecondaryChange From Baseline in the Evening Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score at Week 12

Participants rated the intensity of pain in the CRPS-affected limb twice each day in a diary. The PI-NRS is an eleven point scale with 0=no pain and 10=worst pain imaginable. The evening pain ratings at baseline and Week 12 are compared. Negative changes indicate improvement in level of pain.

Time frame:
Day 0, week 12
Reported as:
Mean · units on a scale
Change From Baseline in the Evening Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score at Week 12
units on a scaleLenalidomidePlacebo to Lenalidomide
Change From Baseline in the Evening Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score at Week 12-0.6 ± 1.69-0.4 ± 1.53
SecondaryChange From Baseline in Daily Sleep Assessment Average Score at Week 12

Participants rated how much CRPS pain interfered with their sleep each day in a diary. The Sleep Assessment uses an eleven point scale for four questions. Questions concern ability to fall asleep, ability to stay asleep, how refreshed the participant feels upon waking and how alert the participant is during the day. All use a scale of 0-10, where the higher number is the positive response (e.g. 0=Pain completely interferes with sleep and 10=Pain does not interfere). The mean of all four responses was calculated if at least 3 of the 4 questions had a value. Week 12 values are compared to baseline values. Positive change values indicate improvement.

Time frame:
Day 0, week 12
Reported as:
Mean · units on a scale
Change From Baseline in Daily Sleep Assessment Average Score at Week 12
units on a scaleLenalidomidePlacebo to Lenalidomide
Change From Baseline in Daily Sleep Assessment Average Score at Week 120.7 ± 1.480.7 ± 1.42
SecondaryChange From Baseline in Activity Level Rating Using a Numeric Rating Scale (NRS) at Week 12

Participants rated how the activity level on a given day compares with their activity level prior to the start of treatment. A seven-point scale is used with -3=much worse and +3=much better. Positive change values indicate improvement.

Time frame:
Day 0, week 12
Reported as:
Mean · units on a scale
Change From Baseline in Activity Level Rating Using a Numeric Rating Scale (NRS) at Week 12
units on a scaleLenalidomidePlacebo to Lenalidomide
Change From Baseline in Activity Level Rating Using a Numeric Rating Scale (NRS) at Week 120.1 ± 1.080.2 ± 1.09
SecondaryChange From Baseline in Participant Assessment of CRPS Symptoms Total Score at Week 12

Participants rated twelve CRPS symptoms using a four-point rating scale in which 1=the most positive outcome and 4= the most negative outcome for a total scale of 12-48. Week 12 values are compared to baseline values. Negative change values indicate improvement.

Time frame:
Day 0, week 12
Reported as:
Mean · units on a scale
Change From Baseline in Participant Assessment of CRPS Symptoms Total Score at Week 12
units on a scaleLenalidomidePlacebo to Lenalidomide
Change From Baseline in Participant Assessment of CRPS Symptoms Total Score at Week 12-2.4 ± 6.27-1.4 ± 5.83
SecondaryChange From Baseline in "Mechanically Evoked" (Allodynia) Numeric Rating Scale (NRS) Score at Week 12

The investigator rated the degree of allodynia on both the CRPS-affected limb on an eleven-point scale where 0=no pain and 10=worst pain imaginable. This outcome compares the baseline values for the CRPS affected-limb to the values at week 12. Negative change values indicate improvement.

Time frame:
Day 0, week 12
Reported as:
Mean · units on a scale
Change From Baseline in "Mechanically Evoked" (Allodynia) Numeric Rating Scale (NRS) Score at Week 12
units on a scaleLenalidomidePlacebo to Lenalidomide
Change From Baseline in "Mechanically Evoked" (Allodynia) Numeric Rating Scale (NRS) Score at Week 12-0.8 ± 2.38-0.1 ± 2.64
SecondaryDifference in Allodynia Rating Between the CRPS-affected Limb and the Normal Limb at Week 12

The investigator rated the degree of allodynia on both the CRPS-affected limb and the normal (or less-affected) limb on an eleven-point scale where 0=no pain and 10=worst pain imaginable. This outcome compares the values for the CRPS affected-limb to the normal limb at week 12.

Time frame:
Week 12
Reported as:
Mean · units on a scale
Difference in Allodynia Rating Between the CRPS-affected Limb and the Normal Limb at Week 12
units on a scaleLenalidomidePlacebo to Lenalidomide
Difference in Allodynia Rating Between the CRPS-affected Limb and the Normal Limb at Week 123.7 ± 3.234.1 ± 3.41
SecondaryChange From Baseline in the Brief Pain Inventory (BPI) Total Score at Week 12

Participants completed the Brief Pain Inventory which asks twelve questions that are rated on an eleven-point scale in which 0=most positive outcome and 10=the most negative outcome for a total scale of 0-120. BPI contains questions that concern the level of pain over the last week and the level of pain right now, the extent to which pain interfered with sleep, normal activities, ability to work, relationships, walking etc. Week 12 values are compared to baseline values. Negative change values indicate improvement.

Time frame:
Day 0, week 12
Reported as:
Mean · units on a scale
Change From Baseline in the Brief Pain Inventory (BPI) Total Score at Week 12
units on a scaleLenalidomidePlacebo to Lenalidomide
Change From Baseline in the Brief Pain Inventory (BPI) Total Score at Week 12-4.8 ± 13.03-3.7 ± 12.22
SecondaryChange From Baseline in the Profile of Mood States (POMS) at Week 12

Participants completed the Profile of Mood States questionnaire that asks participants to rate how each of 65 words reflected their mood in the past week on a 5-point scale with 0=not at all and 4=extremely for a total scale of 0-260. Week 12 values are compared to baseline values. Negative change values indicate improvement.

Time frame:
Day 0, week 12
Reported as:
Mean · units on a scale
Change From Baseline in the Profile of Mood States (POMS) at Week 12
units on a scaleLenalidomidePlacebo to Lenalidomide
Change From Baseline in the Profile of Mood States (POMS) at Week 12-9.6 ± 33.99-4.5 ± 33.91
SecondaryPatient Global Impression of Change (PGIC) at Week 12

The Patient Global Impression of Change asks the question: Overall, how would you rate your CRPS condition since the start of study drug? Answers are represented on a seven-point scale with -3=much worst and +3=much better.

Time frame:
Week 12
Reported as:
Mean · units on a scale
Patient Global Impression of Change (PGIC) at Week 12
units on a scaleLenalidomidePlacebo to Lenalidomide
Patient Global Impression of Change (PGIC) at Week 120.2 ± 1.450.2 ± 1.41
SecondaryParticipants Who Had a Change to CRPS Pain Medication During the Treatment Period

Participants who had any change in CRPS medication during the double-blind treatment period (up to week 12) are summarized. Changes include additions, discontinuations or dosage change of CRPS medication(s).

Time frame:
Day 1 to week 12
Reported as:
Number · participants
Participants Who Had a Change to CRPS Pain Medication During the Treatment Period
participantsLenalidomidePlacebo to Lenalidomide
Change to CRPS medication(s)117
No change to CRPS medication7686
SecondaryChange From Baseline in the Maximal Composite Motor Nerve Conduction Velocity at Week 12

An electrophysiological evaluation using standard electrophysiological and electromyography to measure the speed and extent of nerve conduction. Week 12 values are compared to baseline values for maximal motor nerve conduct velocity.

Time frame:
Day 0, week 12
Reported as:
Mean · meters/second
Change From Baseline in the Maximal Composite Motor Nerve Conduction Velocity at Week 12
meters/secondLenalidomidePlacebo to Lenalidomide
Change From Baseline in the Maximal Composite Motor Nerve Conduction Velocity at Week 120.3 ± 1.560.1 ± 2.14
SecondaryChange From Baseline in the Maximal Composite Sensory Nerve Conduction Velocity at Week 12

An electrophysiological evaluation using standard electrophysiological and electromyography to measure the speed and extent of nerve conduction. Week 12 values are compared to baseline values for maximal sensory nerve conduct velocity.

Time frame:
Day 0, week 12
Reported as:
Mean · meters/second
Change From Baseline in the Maximal Composite Sensory Nerve Conduction Velocity at Week 12
meters/secondLenalidomidePlacebo to Lenalidomide
Change From Baseline in the Maximal Composite Sensory Nerve Conduction Velocity at Week 121.2 ± 3.510.1 ± 3.41
SecondaryParticipants With Treatment-Emergent Adverse Events in the Double-Blind Period or the Extension Period

Counts of study participants who had adverse events (AEs) while treated in either the Double-blind or Extension Periods. The NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 was used by the investigator to grade the severity of the AEs: Grade 1=Mild AE, Grade 2=Moderate AE, Grade 3=Severe AE, Grade 4=Life-threatening or disabling AE, Grade 5=Death related to AE. AEs are also summarized by whether they were serious, related to treatment and whether the AE caused treatment to be altered. A serious AE (SAE) was any event that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or congenital anomaly/birth defect or was an important medical event could have jeopardized the patient's safety or required medical or surgical intervention to prevent one of the outcomes listed above.

Time frame:
Day 1 up to week 158
Reported as:
Number · participants
Participants With Treatment-Emergent Adverse Events in the Double-Blind Period or the Extension Period
participantsLenalidomidePlacebo to Lenalidomide
Adverse event (AE)8385
Serious adverse event (SAE)1216
AE leading to study drug discontinuation2929
AE leading to dose reduction or interruption108
Treatment-related AE6866
Treatment-related SAE15
Grade 2 or higher AE6368
Grade 3 or higher AE1518

Adverse events

Collected over Day 1 up to week 158, covering both the double-blind treatment and extension periods.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide—12/87 (13.8%)77/87 (88.5%)
Placebo to Lenalidomide—16/93 (17.2%)72/93 (77.4%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventLenalidomidePlacebo to Lenalidomide
Joint sprainInjury, poisoning and procedural complications2/870/93
Pregnancy NOSPregnancy, puerperium and perinatal conditions2/870/93
Deep vein thrombosisVascular disorders1/872/93
Foot fractureInjury, poisoning and procedural complications1/870/93
ThrombosisVascular disorders1/870/93
Blood human chorionic gonadotropin positiveInvestigations1/870/93
Blood potassium decreasedInvestigations1/870/93
Pregnancy test false positiveInvestigations1/870/93
Neuropathic painNervous system disorders1/871/93
Sick sinus syndromeCardiac disorders1/870/93
Most frequent other events
Showing 10 of 20
Most frequent other events
EventLenalidomidePlacebo to Lenalidomide
Rash NOSSkin and subcutaneous tissue disorders24/879/93
NauseaGastrointestinal disorders14/8715/93
HeadacheNervous system disorders9/8713/93
FatigueGeneral disorders9/8712/93
Diarrhoea NOSGastrointestinal disorders11/8710/93
DizzinessNervous system disorders9/876/93
PruritusSkin and subcutaneous tissue disorders8/874/93
ConstipationGastrointestinal disorders8/875/93
InsomniaPsychiatric disorders7/875/93
Dry skinSkin and subcutaneous tissue disorders6/872/93

Baseline characteristics

Safety population

Age Continuous
Age Continuous(years)LenalidomidePlacebo to LenalidomideTotal
Mean43.9 ± 11.3745.1 ± 11.0644.5 ± 11.20
Sex: Female, Male
Sex: Female, Male(Participants)LenalidomidePlacebo to LenalidomideTotal
Female6579144
Male221436
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)LenalidomidePlacebo to LenalidomideTotal
White8186167
Black347
Hispanic134
Asian/Pacific Islander202
08

Study locations

27 sites
  • Pivotal Research Centers
    Peoria, Arizona 85381, United States
  • UCSD Center for Pain and Palliative Medicine
    La Jolla, California 92093, United States
  • Loma Linda Institution
    Loma Linda, California 92354, United States
  • Space Coast Neurology
    Palm Bay, Florida 32905, United States
  • Northwestern University
    Chicago, Illinois 60611-2908, United States
  • Rehab Institute of Chicago
    Chicago, Illinois 60611, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02115, United States
  • Baystate Medical Center
    Springfield, Massachusetts 01199, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University Pain Mgmt Ctr
    St. Louis, Missouri 63141, United States
  • Hospital for Joint Disease
    New York, New York 10003, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • UNC Hospitals University of North Carolina
    Chapel Hill, North Carolina 27599-7010, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Womack Army Medical Center
    Fort Bragg, North Carolina 28310, United States
  • Carolinas Pain Institute, P.A. & the Center for Clinical Research, LLC
    Winston Salem, North Carolina 27103, United States
  • Research Institute of Greater Dayton
    Dayton, Ohio 45432, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Lehigh Valley Hospital
    Allentown, Pennsylvania 18103, United States
  • Knobler Institute of Neurologic Disease
    Ft. Washington, Pennsylvania 19034, United States
  • Drexel University College of Medicine Department of Neurology Rm 7102
    Philadelphia, Pennsylvania 19102, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Texas Tech Medical Center Department of Anesthesiology
    Lubbock, Texas 79430, United States
  • University of Virginia Pain Management Center
    Charlottesville, Virginia 22903, United States
  • Swedish Pain Services
    Seattle, Washington 98104, United States
09

References and documents

Publications

  • Manning DC, Alexander G, Arezzo JC, Cooper A, Harden RN, Oaklander AL, Raja SN, Rauck R, Schwartzman R. Lenalidomide for complex regional pain syndrome type 1: lack of efficacy in a phase II randomized study. J Pain. 2014 Dec;15(12):1366-76. doi: 10.1016/j.jpain.2014.09.013. Epub 2014 Oct 2. PubMed 25283471 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2005, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 5 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2005
First posted
May 4, 2005
Start
Feb 2005
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results first posted
Aug 28, 2013
Last update
Aug 28, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00109772
Responsible party
Sponsor
First posted
May 4, 2005
Start date
Feb 2005
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
Aug 28, 2013
Last update
Aug 28, 2013

Study contacts

Donald C Manning, MD, PhD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion